These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 27726115)

  • 61. Early Reduction of Glucose Consumption Is a Biomarker of Kinase Inhibitor Efficacy Which Can Be Reversed with GLUT1 Overexpression in Lung Cancer Cells.
    Ghezzi C; Perez S; Ryan K; Wong A; Chen BY; Damoiseaux R; Clark PM
    Mol Imaging Biol; 2023 Jun; 25(3):541-553. PubMed ID: 36284040
    [TBL] [Abstract][Full Text] [Related]  

  • 62. MET amplification and epithelial-to-mesenchymal transition exist as parallel resistance mechanisms in erlotinib-resistant, EGFR-mutated, NSCLC HCC827 cells.
    Jakobsen KR; Demuth C; Madsen AT; Hussmann D; Vad-Nielsen J; Nielsen AL; Sorensen BS
    Oncogenesis; 2017 Apr; 6(4):e307. PubMed ID: 28368392
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Image Findings of Rare Case of Peritoneal Carcinomatosis from Non Small Cell Lung Cancer and Response to Erlotinib in F-18 FDG Positron Emission Tomography/Computed Tomography.
    Kamaleshwaran KK; Joseph J; Kalarikal RK; Shinto AS
    Indian J Nucl Med; 2017; 32(2):140-142. PubMed ID: 28533646
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [18 F]FDG-PET imaging is an early non-invasive pharmacodynamic biomarker for a first-in-class dual MEK/Raf inhibitor, RO5126766 (CH5126766), in preclinical xenograft models.
    Tegnebratt T; Lu L; Lee L; Meresse V; Tessier J; Ishii N; Harada N; Pisa P; Stone-Elander S
    EJNMMI Res; 2013 Sep; 3(1):67. PubMed ID: 24041012
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The influence of tumor heterogeneity on sensitivity of EGFR-mutant lung adenocarcinoma cells to EGFR-TKIs.
    Sun L; Li YY; Ma JT; Zhang SL; Huang LT; Han CB
    Transl Cancer Res; 2019 Sep; 8(5):1834-1844. PubMed ID: 35116934
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Evaluation of quantitative modeling methods in whole-body, dynamic [
    Petrulli JR; Zheng M; Huang Y; Nabulsi NB; Goldberg SB; Contessa JN; Morris ED
    Am J Nucl Med Mol Imaging; 2021; 11(2):143-153. PubMed ID: 34079641
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Evaluating Imaging Biomarkers of Acquired Resistance to Targeted EGFR Therapy in Xenograft Models of Human Head and Neck Squamous Cell Carcinoma.
    Baker LCJ; Sikka A; Price JM; Boult JKR; Lepicard EY; Box G; Jamin Y; Spinks TJ; Kramer-Marek G; Leach MO; Eccles SA; Box C; Robinson SP
    Front Oncol; 2018; 8():271. PubMed ID: 30083516
    [No Abstract]   [Full Text] [Related]  

  • 68. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
    Langer CJ; Gadgeel SM; Borghaei H; Papadimitrakopoulou VA; Patnaik A; Powell SF; Gentzler RD; Martins RG; Stevenson JP; Jalal SI; Panwalkar A; Yang JC; Gubens M; Sequist LV; Awad MM; Fiore J; Ge Y; Raftopoulos H; Gandhi L;
    Lancet Oncol; 2016 Nov; 17(11):1497-1508. PubMed ID: 27745820
    [TBL] [Abstract][Full Text] [Related]  

  • 69. MEK inhibitors against MET-amplified non-small cell lung cancer.
    Chiba M; Togashi Y; Tomida S; Mizuuchi H; Nakamura Y; Banno E; Hayashi H; Terashima M; De Velasco MA; Sakai K; Fujita Y; Mitsudomi T; Nishio K
    Int J Oncol; 2016 Dec; 49(6):2236-2244. PubMed ID: 27748834
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A long-term survivor of non-small-cell lung cancer harboring concomitant EGFR mutation and ALK translocation.
    Imamura F; Inoue T; Kimura M; Nishino K; Kumagai T
    Respir Med Case Rep; 2016; 19():137-139. PubMed ID: 27747151
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Erlotinib induces the human non-small-cell lung cancer cells apoptosis via activating ROS-dependent JNK pathways.
    Shan F; Shao Z; Jiang S; Cheng Z
    Cancer Med; 2016 Nov; 5(11):3166-3175. PubMed ID: 27726288
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Effects of epidermal growth factor receptor-tyrosine kinase inhibitors alone on EGFR-mutant non-small cell lung cancer with brain metastasis.
    Zhang Q; Zhang X; Yan H; Jiang B; Xu C; Yang J; Chen Z; Su J; Wu YL; Zhou Q
    Thorac Cancer; 2016 Nov; 7(6):648-654. PubMed ID: 27755835
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Synonymous EGFR variant p.Q787Q is neither prognostic nor predictive in patients with lung adenocarcinoma.
    Leichsenring J; Volckmar AL; Magios N; Morais de Oliveira CM; Penzel R; Brandt R; Kirchner M; Bozorgmehr F; Thomas M; Schirmacher P; Warth A; Endris V; Stenzinger A
    Genes Chromosomes Cancer; 2017 Mar; 56(3):214-220. PubMed ID: 27750395
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study.
    Oza AM; Selle F; Davidenko I; Korach J; Mendiola C; Pautier P; Chmielowska E; Bamias A; DeCensi A; Zvirbule Z; González-Martín A; Hegg R; Joly F; Zamagni C; Gadducci A; Martin N; Robb S; Colombo N
    Int J Gynecol Cancer; 2017 Jan; 27(1):50-58. PubMed ID: 27749456
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis.
    Lee CK; Man J; Lord S; Links M; Gebski V; Mok T; Yang JC
    J Thorac Oncol; 2017 Feb; 12(2):403-407. PubMed ID: 27765535
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cells.
    Faião-Flores F; Alves-Fernandes DK; Pennacchi PC; Sandri S; Vicente AL; Scapulatempo-Neto C; Vazquez VL; Reis RM; Chauhan J; Goding CR; Smalley KS; Maria-Engler SS
    Oncogene; 2017 Mar; 36(13):1849-1861. PubMed ID: 27748762
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Erlotinib Induced Fatal Interstitial Lung Disease in a Patient with Metastatic Non-Small Cell Lung Cancer: Case Report and Review of Literature.
    Mangla A; Agarwal N; Carmel C; Lad T
    Rare Tumors; 2016 Sep; 8(3):6410. PubMed ID: 27746884
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The role of alectinib in the treatment of advanced ALK-rearranged non-small-cell lung cancer.
    Srinivasamaharaj S; Salame BK; Rios-Perez J; Kloecker G; Perez CA
    Expert Rev Anticancer Ther; 2016 Dec; 16(12):1227-1233. PubMed ID: 27744726
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Toxic epidermal necrolysis induced by vemurafenib after nivolumab failure.
    Arenbergerova M; Mrazova I; Horazdovsky J; Sticova E; Fialova A; Arenberger P
    J Eur Acad Dermatol Venereol; 2017 May; 31(5):e253-e254. PubMed ID: 27739125
    [No Abstract]   [Full Text] [Related]  

  • 80. HCRP1 is downregulated in non-small cell lung cancer and regulates proliferation, invasion, and drug resistance.
    Du Y; Wang P; Sun H; Yang J; Lang X; Wang Z; Zang S; Chen L; Ma J; Sun D
    Tumour Biol; 2016 Oct; ():. PubMed ID: 27739029
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.